Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

Company Profiles
Target Profiles
Product Profiles

Explore BCIQ profiles by entering a company name.

REQUEST A FREE TRIAL

Solasia Pharma K.K.

Name: Solasia Pharma K.K. - BioCentury Company Profiles - BCIQ
Creator: Biocentury

Headquarters: Tokyo, Japan

Website: http://www.solasia.co.jp

Year Founded: 2006

Status: Public

Industry Sector: HealthTechnology

CEO: Yoshihiro Arai, MBA

Number Of Employees: 23

Enterprise Value: $40,297,621

PE Ratio: -3.28

Exchange/Ticker 1: Tokyo:4597

Exchange/Ticker 2: N/A

Latest Market Cap: $46,203,033

BioCentury | Jun 7, 2022

Emerging Company Profile

LUCA: off-the-shelf mitochondria for wide-ranging applications

Tokyo-based LUCA believes mitochondrial transplant can restore function after heart attack, treat rare diseases, enhance cell therapies and more

BioCentury | Aug 15, 2020

Product Development

Aug. 14 Quick Takes: Challenge data for CanSino COVID-19 vaccine; plus Warp Speed-McKesson, BioMarin, TG, Solasia-Isofol

CanSino vaccine stops COVID-19 in mice, ferretsMice given a single intranasal immunization with Ad5-nCoV from CanSino Biologics Inc. (HKEX:6185; Shanghai:688185) and then challenged with mouse-adapted

BioCentury | Dec 31, 2019

Company News